Matching diagnostics development to clinical need: Target product profile development for a point of care test for community-acquired lower respiratory tract infection

PLoS One. 2018 Aug 1;13(8):e0200531. doi: 10.1371/journal.pone.0200531. eCollection 2018.

Abstract

Background: Point of care tests (POCTs) are increasingly being promoted for guiding the primary medical care of community acquired lower respiratory tract infections (CA-LRTI). POCT development has seldom been guided by explicitly identified clinical need and requirements of the intended users. Approaches for identifying POCT priorities and developing target product profiles (TPPs) for POCTs in primary medical care are not well developed, and there is no published TPP for a CA-LRTI POCT aimed at developed countries.

Methods: We conducted workshops with expert stakeholders and a survey with primary care clinicians to produce a target product profile (TPP) to guide the development of a clinically relevant and technologically feasible POCT for CA-LRTI.

Results: Participants with clinical, academic, industrial, technological and basic scientific backgrounds contributed to four expert workshops, and 45 practicing primary care clinicians responded to an online survey and prioritised community-acquired pneumonia (CAP) as the CA-LRTI where a new POCT was most urgently needed. Consensus was reached on a TPP document that included information on the intended niche in the clinical pathway in primary medical care; diagnostic product specification (intended use statement and test concept), and minimum and ideal user specifications. Clinicians minimum requirements of a CA-LRTI POCT included the use of minimally invasive samples, a result in less than 30 minutes, no more than a single preparation step, minimum operational requirements, and detection of common respiratory pathogens and their resistance to commonly prescribed antibiotics.

Conclusions: This multidisciplinary, multistage partnership approach generated a clinically-driven TPP for guiding the development of a new POCT, and this approach as well as the TPP itself may be useful to others developing a new POCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Consensus Development Conferences as Topic
  • Europe
  • General Practitioners / psychology
  • Humans
  • Pneumonia / diagnosis
  • Point-of-Care Systems*
  • Primary Health Care
  • Respiratory Tract Infections / diagnosis*
  • Surveys and Questionnaires

Grants and funding

This study was part of the RAPP-ID project (https://www.uantwerpen.be/en/projects/rapp-id/about-rapp-id/) funded by the Innovative Medicines Initiative IIMI-JU-02-2009-04 - Infectious Diseases - Diagnostic Tools. Project ID/Grant Agreement number: 115153, Coordinator - Professor Herman Goossens), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA companies and IMI Associated Partners do not receive any EU funding through IMI, but contribute to IMI through 'in kind' contributions including the time of staff employed by EFPIA companies directly working on IMI projects. The funder provided support in the form of salaries for authors (MG, NAF, KH, JV, HG, AW, CCB), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript .JV was employed by the commercial company, "Janssen Diagnostics BVBA" (one of the 5 EFPIA member companies of the RAPP-JD consortium. Janssen Diagnostics BVBA provided support in the form of salary for author JV, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the author contributions section.